1220870-05-2

Upstream product

• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 1220708-69-9 4-(5-(butylamino)-1,3,4-thiadiazol-2-yl)-2,6-dimethylphenol 
• 1220708-59-7 N-butyl-5-(4-methoxy-3,5-dimethylphenyl)-1,3,4-thiadiazol-2-amine 
• 456-64-4 phenyl trifluoromethanesulfonamide 
• 6610-31-7 4-butyl-3-thiosemicarbazide 
• 592-82-5 butyl isothiocyanate 

Relevant academic research and scientific papers

New thiadiazole derivatives

The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

NEW THIADIAZOLE DERIVATIVES

The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful In the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

NEW 2-AMIDOTHIADIAZOLE DERIVATIVES

New 2-amidothiadiazole derivatives having the chemical structure of formula (I) or pharmaceutically acceptable salts or N-oxides thereof as agonists of S1P1 receptors.